Helus Pharma's Rally Puts Phase-3 Data in the Spotlight as New CEO Takes the Helm
Published on 08/09/2026 at 06:22 | Redaktion boerse-global.de
A stock that climbs 48.47 percent in a single week tends to attract attention — and scrutiny in equal measure. That's the situation facing Helus Pharma, the company formerly known as Cybin, which closed Friday at $11.61, just a cent shy of its 52-week high of $11.62. The surge caps a remarkable 30-day stretch that saw the shares advance 86.36 percent, a move that has pushed the relative strength index to 85 — a level that technical analysts would describe as deeply overbought.
The catalyst for the recent acceleration came on August 3, when the company announced the appointment of Michael Halstead as chief executive officer, effective immediately. Halstead arrives with 25 years of industry experience, most recently serving as president of Intra-Cellular Therapies, where he oversaw the commercialization of CAPLYTA, a drug indicated for psychiatric conditions. Investors responded enthusiastically, pushing the stock up roughly 13 percent on Wednesday before the rally extended through the week.
A Pipeline Nearing Its Moment of Truth
Halstead's arrival coincides with a pivotal juncture for the company's lead asset. Helus Pharma completed enrollment on July 21 for APPROACH, its pivotal Phase-3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder. The trial has enrolled 223 adults with moderate-to-severe MDD who had previously shown an inadequate response to conventional antidepressants. Topline results are expected in the fourth quarter of 2026, and the program carries Breakthrough Therapy Designation from the FDA.
A second registrational study, EMBRACE, continues to recruit patients as part of the broader PARADIGM program. The company is simultaneously laying groundwork for potential commercialization, with Halstead tasked with steering the clinical pipeline into its late-stage phase and building the infrastructure for a possible market launch.
While clinical milestones drive investor sentiment, workplace safety remains a fundamental responsibility for any growing organisation. As companies expand operations and bring on new staff, documenting workplace hazards becomes increasingly critical. A free toolkit with 41 ready-to-use templates and checklists helps you manage risk assessments efficiently. Download the free Risk Assessment Toolkit
Wall Street Takes Notice — and the Sector Shifts
The appointment follows a flurry of analyst activity that began in late July. On July 27, Wells Fargo analyst Benjamin Burnett initiated coverage of Helus Pharma with an Overweight rating and a $16 price target. Burnett pointed to data from Compass Pathways' COMP360 program as validation for HLP003 in treatment-resistant depression, arguing that the valuation at the time offered an attractive risk-reward profile ahead of the Phase-3 readout. Wells Fargo simultaneously initiated Compass Pathways at Equal Weight and GH Research at Overweight — a signal that the entire psychedelics development space is undergoing a reassessment, not just Helus Pharma in isolation.
The regulatory environment has shifted in the sector's favor as well. Mid-July brought finalized FDA guidance on clinical trial design for psychedelics research, which industry observers interpreted as a more receptive regulatory stance. That development, coupled with a wave of major pharmaceutical investments in the space, provides structural tailwinds that extend beyond any single company's news flow.
The Balance Sheet Behind the Rally
The recent share price strength follows a period of financial consolidation. On June 25, the company closed a capital raise of approximately 10.3 million common shares at $4.85 per share, generating gross proceeds of about $50 million. The offering was co-managed by Cantor Fitzgerald & Co. and Barclays Capital. As of the end of March, Helus Pharma held $157.3 million in cash, providing runway into the Phase-3 data readout.
Those funds will be needed. For the fiscal year ending March 31, 2026, the company reported a net loss of $148.0 million, up from $81.6 million in the prior year, with operating cash burn of $131.7 million. The loss per share came in at CAD 5.88, compared with CAD 5.59 a year earlier. The company's January move to the Nasdaq Global Market under the ticker HELP was designed to boost visibility among institutional investors, though the financial profile remains firmly in loss-making territory.
A Cautionary Signal From Inside
Not all recent insider activity points to unbridled confidence. On July 13, Greg Cavers sold roughly 71,000 shares at approximately $6.10 apiece — a disposal that represented 45 percent of his direct holdings and marked the largest insider sale in the past three months. While insider selling at a fraction of the current price doesn't necessarily signal a loss of faith, it hardly constitutes a ringing endorsement from within.
For companies navigating periods of transition and growth, maintaining compliance with health and safety regulations is essential. Over 37,000 UK businesses rely on a comprehensive toolkit covering key regulations like the Health & Safety at Work Act 1974 and COSHH. Get the free Health & Safety Toolkit
What Comes Next
The market now faces a two-sided narrative. On one hand, the company has delivered tangible progress: a seasoned CEO with commercial experience, completed enrollment in a pivotal trial, a more favorable regulatory climate, and an analyst with a clear price target. On the other, the technical picture suggests expectations have run well ahead of confirmed fundamentals. The RSI reading of 85 puts the stock in rarefied air.
The APPROACH data in the fourth quarter will serve as the ultimate arbiter of whether the current valuation is justified. In the meantime, two upcoming events could provide near-term catalysts or correctives: the quarterly results expected around August 11 and the annual shareholder meeting scheduled for September 22. With the stock trading within striking distance of its $16 price target just two weeks after that target was set, the market has already priced in a considerable degree of success. The margin for disappointment is correspondingly thin.
